Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs TotalEnergies SE (TTE) Price & Performance

AbCellera Biologics IncTrade
TotalEnergies SETrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs TotalEnergies SE — how do they compare? AbCellera Biologics Inc trades at $10.33 (market cap $2.99B), while TotalEnergies SE trades at $86.9 (market cap $196.06B). The key difference: TotalEnergies SE is far larger — about 65.6× AbCellera Biologics Inc's market cap, and TotalEnergies SE pays a 4.82% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLTTE
Market Cap
$2.99B$196.06B
Sector
HealthEnergy
52-Week High
$9.76$93.60
52-Week Low
$2.78$57.39
Enterprise Value
$2.58B$227.06B
Dividend Yield
4.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.

The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.

TotalEnergies SE

TotalEnergies (TTE) trades at $87.46, down 0.57% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed quarterly beats, while revenue declined to $182.34B in 2025. The company is expanding in renewables, acquiring Shell's European onshore renewables business and partnering on a Cyprus gas field development.

TTE offers value with a P/E of 11.01 and a 57.58% buy rating from analysts, targeting $94.00. Risks include declining revenue trends, legal challenges from climate litigation, and oil price volatility. The stock presents a balanced opportunity with income from dividends but faces execution risks in energy transition.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About TotalEnergies SE

TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.

Read more on TTE